Craig L. Tendler, M.D.
Drug Development Advisor
Craig L. Tendler is an accomplished biopharmaceutical drug developer with more than three decades of experience advancing practice-changing oncology medicines through clinical development and commercialization.
Most recently, Craig served as Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs at Johnson & Johnson Innovative Medicine. In this position, Craig was responsible for creating and overseeing robust development plans, including optimal integration of biomarkers and comprehensive data generation activities for all products in the J&J oncology portfolio, from early development and proof of concept through registration and lifecycle management.
Craig has overseen and coordinated more than 30 major drug approvals by national regulatory agencies, including 15 New Drug Applications (NDAs) by the U.S. Food and Drug Administration (FDA). At J&J, he and his team collaborated with the FDA and European Medicines Agency(EMA) to secure the worldwide approvals of transformational treatments in prostate cancer (ZYTIGA®, AKEEGA®, and ERLEADA®), hematologic malignancies (DARZALEX®, CARVYKTI®, TECVAYLI®, TALVEY®, IMBRUVICA®), as well as for lung (RYBREVANT®) and bladder cancer (BALVERSA®). Craig has also been instrumental in achieving 13 FDA breakthrough designations intended to accelerate the development of therapeutics for the treatment of serious oncological conditions.
Prior to joining J&J Innovative Medicine, Craig was an Assistant Professor of Pediatrics/Hematology-Oncology at the Mount Sinai School of Medicine and a NIH physician-scientist grant recipient and research fellow at the National Cancer Institute in Bethesda, Maryland.
After earning his undergraduate degree from Cornell University, Craig graduated from the Mount Sinai School of Medicine in New York City with high honors and induction into the Alpha Omega Alpha Medical Society.
